Dimebon (latrepirdine) / BioXcel, BIGESPAS - LARVOL DELTA

Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia (clinicaltrials.gov) - P3 | N=450 | Recruiting | Sponsor: Bigespas LTD

New P3 trial • Alzheimer's Disease • CNS Disorders • Dementia

DMB-I in the Treatment of Alzheimer Type Dementia (clinicaltrials.gov) - P2 | N=133 | Completed | Sponsor: Bigespas LTD | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023 (BioXcel Therapeutics Press Release) - "To discuss agitation relief in Alzheimer'ss disease and BXCL502 as a potential treatment."

Live event